Shilpa Pharma Lifesciences’ Raichur API facility clears second consecutive FDA inspection with no… EP News Bureau Apr 9, 2025 Shilpa Medicare's Unit-2 API facility in Raichur, India passes March 2025 FDA audit without Form 483 observations, reinforcing…
Granules Pharma completes USFDA PADE Inspection with zero observations EP News Bureau Aug 4, 2023 The inspection was conducted at Granules Pharmaceuticals from July 31, 2023 to August 03, 2023
